中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(5): 1204-1211

Role of macrophage polarization and its crosstalk with neighboring cells in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.05.032
  • 1.

    Graduate School of Guangxi University of Chinese Medicine, Nanning 530200, China

  • 2.

    Second Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation of China (81760844);

National Science and Technology Major Project (2018ZX10725505-001-011);

Guangxi Science and Technology Project (2020GXNSFAA297098);

Guangxi University of Traditional Chinese Medicine Graduate Innovation Project (YCXJ2021058)

More Information
  • Corresponding author: LONG Fuli, longfuli005@163.com (ORCID: 0000-0003-1196-2697)
  • Received Date: 2022-08-31
  • Accepted Date: 2022-10-17
  • Published Date: 2023-05-20
    Abstract
  • Inflammation is closely associated with the development of cancer. Tumor-associated macrophages (TAM) actively participate in tumor-related inflammation and promote tumor growth and metastasis, while under certain conditions, TAM also show cytotoxicity and tumor killing activity and thus inhibit the progression of cancer. Crosstalk between TAM and neighboring cells is closely associated with the progression of hepatocellular carcinoma (HCC) and drug resistance during treatment. This article summarizes the role of macrophages in HCC and the crosstalk between macrophages and other cells, so as to provide new strategies for the clinical diagnosis and treatment of HCC.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    PINTER M, SCHEINER B, PECK-RADOSAVLJEVIC M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups[J]. Gut, 2021, 70(1): 204-214. DOI: 10.1136/gutjnl-2020-321702.
    [2]
    FANG CH, CAI W. Application of artificial intelligence in the diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2022, 38(1): 26-29. DOI: 10.3969/j.issn.1001-5256.2022.01.004.

    方驰华, 蔡伟. 人工智能在原发性肝癌诊疗中的应用[J]. 临床肝胆病杂志, 2022, 38(1): 26-29. DOI: 10.3969/j.issn.1001-5256.2022.01.004.
    [3]
    FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
    [4]
    RIZVI S, WANG J, EL-KHOUEIRY AB. Liver cancer immunity[J]. Hepatology, 2021, 73(Suppl 1): 86-103. DOI: 10.1002/hep.31416.
    [5]
    RITZ T, KRENKEL O, TACKE F. Dynamic plasticity of macrophage functions in diseased liver[J]. Cell Immunol, 2018, 330: 175-182. DOI: 10.1016/j.cellimm.2017.12.007.
    [6]
    ESHGHJOO S, KIM DM, JAYARAMAN A, et al. Macrophage polarization in atherosclerosis[J]. Genes (Basel), 2022, 13(5): 756. DOI: 10.3390/genes13050756.
    [7]
    ANDERSON NR, MINUTOLO NG, GILL S, et al. Macrophage-based approaches for cancer immunotherapy[J]. Cancer Res, 2021, 81(5): 1201-1208. DOI: 10.1158/0008-5472.CAN-20-2990.
    [8]
    SHAPOURI-MOGHADDAM A, MOHAMMADIAN S, VAZINI H, et al. Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018, 233(9): 6425-6440. DOI: 10.1002/jcp.26429.
    [9]
    OSIPOV A, MURPHY A, ZHENG L. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy[J]. Adv Cancer Res, 2019, 143: 63-144. DOI: 10.1016/bs.acr.2019.03.002.
    [10]
    REICHEL D, TRIPATHI M, PEREZ JM. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment[J]. Nanotheranostics, 2019, 3(1): 66-88. DOI: 10.7150/ntno.30052.
    [11]
    XIANG W, SHI R, KANG X, et al. Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression[J]. Nat Commun, 2018, 9(1): 2574. DOI: 10.1038/s41467-018-04999-8.
    [12]
    HAM S, LIMA LG, LEK E, et al. The impact of the cancer microenvironment on macrophage phenotypes[J]. Front Immunol, 2020, 11: 1308. DOI: 10.3389/fimmu.2020.01308.
    [13]
    MEI J, XIAO Z, GUO C, et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis[J]. Oncotarget, 2016, 7(23): 34217-34228. DOI: 10.18632/oncotarget.9079.
    [14]
    CHEN Y, SONG Y, DU W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression[J]. J Biomed Sci, 2019, 26(1): 78. DOI: 10.1186/s12929-019-0568-z.
    [15]
    BOHN T, RAPP S, LUTHER N, et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages[J]. Nat Immunol, 2018, 19(12): 1319-1329. DOI: 10.1038/s41590-018-0226-8.
    [16]
    YANG Y, YE YC, CHEN Y, et al. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors[J]. Cell Death Dis, 2018, 9(8): 793. DOI: 10.1038/s41419-018-0818-0.
    [17]
    CHEN MM, XIAO X, LAO XM, et al. Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization[J]. Cancer Discov, 2016, 6(10): 1182-1195. DOI: 10.1158/2159-8290.CD-16-0329.
    [18]
    ZHANG YL, LI Q, YANG XM, et al. SPON2 promotes M1-like macrophage recruitment and inhibits hepatocellular carcinoma metastasis by distinct integrin-Rho GTPase-Hippo pathways[J]. Cancer Res, 2018, 78(9): 2305-2317. DOI: 10.1158/0008-5472.CAN-17-2867.
    [19]
    LIU N, WANG X, STEER CJ, et al. MicroRNA-206 promotes the recruitment of CD8+ T cells by driving M1 polarisation of Kupffer cells[J]. Gut, 2022, 71(8): 1642-1655. DOI: 10.1136/gutjnl-2021-324170.
    [20]
    XU J, LIN H, WU G, et al. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 760971. DOI: 10.3389/fonc.2021.760971.
    [21]
    WANG TT, YUAN JH, MA JZ, et al. CTGF secreted by mesenchymal-like hepatocellular carcinoma cells plays a role in the polarization of macrophages in hepatocellular carcinoma progression[J]. Biomed Pharmacother, 2017, 95: 111-119. DOI: 10.1016/j.biopha.2017.08.004.
    [22]
    SUN Y, WU L, ZHONG Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184(2): 404-421. DOI: 10.1016/j.cell.2020.11.041.
    [23]
    LI X, YAO W, YUAN Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J]. Gut, 2017, 66(1): 157-167. DOI: 10.1136/gutjnl-2015-310514.
    [24]
    LI X, CHEN L, PENG X, et al. Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor[J]. Front Oncol, 2022, 12: 911410. DOI: 10.3389/fonc.2022.911410.
    [25]
    GUO B, LI L, GUO J, et al. M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(27): 44465-44476. DOI: 10.18632/oncotarget.17973.
    [26]
    WEI Y, SHI D, LIANG Z, et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells[J]. J Hepatol, 2019, 71(6): 1206-1215. DOI: 10.1016/j.jhep.2019.08.034.
    [27]
    SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153(3): 812-826. DOI: 10.1053/j.gastro.2017.06.007.
    [28]
    KE M, ZHANG Z, CONG L, et al. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis[J]. Biomed Pharmacother, 2019, 120: 109523. DOI: 10.1016/j.biopha.2019.109523.
    [29]
    LI Z, LI H, ZHAO ZB, et al. SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signalling-mediated alternative activation of macrophages[J]. J Exp Clin Cancer Res, 2019, 38(1): 469. DOI: 10.1186/s13046-019-1456-9.
    [30]
    PU Z, DUDA DG, ZHU Y, et al. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway[J]. J Transl Med, 2022, 20(1): 212. DOI: 10.1186/s12967-022-03416-5.
    [31]
    DEBACKER JM, GONDRY O, LAHOUTTE T, et al. The prognostic value of CD206 in solid malignancies: A systematic review and meta-analysis[J]. Cancers (Basel), 2021, 13(14): 3422. DOI: 10.3390/cancers13143422.
    [32]
    WU X, LUO H, SHI B, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma[J]. Mol Ther, 2019, 27(8): 1483-1494. DOI: 10.1016/j.ymthe.2019.04.020.
    [33]
    CHEN R, LI Q, XU S, et al. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment[J]. Cancer Cell Int, 2022, 22(1): 73. DOI: 10.1186/s12935-021-02435-4.
    [34]
    LEE TK, GUAN XY, MA S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 26-44. DOI: 10.1038/s41575-021-00508-3.
    [35]
    YIN Z, MA T, LIN Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(11): 9419-9432. DOI: 10.1002/jcb.27259.
    [36]
    ZHONG CQ, ZHANG XP, MA N, et al. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma[J]. Cancer Med, 2018, 7(6): 2629-2640. DOI: 10.1002/cam4.1511.
    [37]
    XUE ST, LI K, GAO Y, et al. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target[J]. Autophagy, 2020, 16(10): 1823-1837. DOI: 10.1080/15548627.2019.1709762.
    [38]
    LIU LZ, ZHANG Z, ZHENG BH, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma[J]. Hepatology, 2019, 69(1): 143-159. DOI: 10.1002/hep.30134.
    [39]
    LIU C, CHIKINA M, DESHPANDE R, et al. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ[J]. Immunity, 2019, 51(2): 381-397. DOI: 10.1016/j.immuni.2019.06.017.
    [40]
    SUNG PS, YOON SK, JANG JW, et al. Inflammation-induced IgA plus tumor-associated macrophages express PD-L1 and causes impaired T cell functionality in hepatocellular carcinoma[J]. Hepatology, 2020, 72(Suppl 1): 780A-781A.
    [41]
    HSU BE, ROY J, MOUHANNA J, et al. C3a elicits unique migratory responses in immature low-density neutrophils[J]. Oncogene, 2020, 39(12): 2612-2623. DOI: 10.1038/s41388-020-1169-8.
    [42]
    ZHOU Z, WANG P, SUN R, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3[J]. J Immunother Cancer, 2021, 9(3): e001946. DOI: 10.1136/jitc-2020-001946.
    [43]
    PENG ZP, JIANG ZZ, GUO HF, et al. Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma[J]. J Hepatol, 2020, 73(4): 906-917. DOI: 10.1016/j.jhep.2020.05.004.
    [44]
    ZHOU SL, DAI Z, ZHOU ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma[J]. Hepatology, 2012, 56(6): 2242-2254. DOI: 10.1002/hep.25907.
    [45]
    WU G, MA Z, CHENG Y, et al. Targeting Gas6/TAM in cancer cells and tumor microenvironment[J]. Mol Cancer, 2018, 17(1): 20. DOI: 10.1186/s12943-018-0769-1.
    [46]
    YANG F, WEI Y, HAN D, et al. Interaction with CD68 and regulation of GAS6 expression by endosialin in fibroblasts drives recruitment and polarization of macrophages in hepatocellular carcinoma[J]. Cancer Res, 2020, 80(18): 3892-3905. DOI: 10.1158/0008-5472.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (378) PDF downloads(51) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return